DIAGNOS Secures Health Canada Licence for AI-Powered Retinal Analysis System
Event summary
- DIAGNOS received a Health Canada Medical Device Licence for its CARA System on July 23, 2026.
- CARA integrates AI-powered analysis modules for retinal conditions like AMD and diabetic retinopathy.
- The licence allows DIAGNOS to serve IRIS The Visual Group and expand into the Canadian optometry market.
- DIAGNOS is pursuing regulatory approvals in Saudi Arabia and the U.S. for CARA System.
The big picture
DIAGNOS' Health Canada approval positions it as one of the first Canadian providers of AI-retinal analysis for optometry. The clearance underscores Quebec's capability to develop globally competitive medical technologies, while DIAGNOS' focus on regulatory expansion signals its ambition to scale in high-growth healthcare markets.
What we're watching
- Regulatory Momentum
- Whether DIAGNOS can secure SFDA and FDA approvals by end-2026, expanding CARA's commercial reach.
- Market Penetration
- The pace at which Canadian optometrists adopt AI-assisted retinal analysis tools.
- Competitive Positioning
- How CARA's explainable AI differentiates it in a growing field of retinal imaging solutions.
Related topics